Insider Selling: USANA Health Sciences (NYSE:USNA) Director Sells 1,058 Shares of Stock
by Amy Steele · The Cerbat GemUSANA Health Sciences, Inc. (NYSE:USNA – Get Free Report) Director Gilbert Fuller sold 1,058 shares of the business’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $17.00, for a total transaction of $17,986.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
USANA Health Sciences Price Performance
Shares of USANA Health Sciences stock traded down $0.26 during trading on Friday, reaching $16.88. 201,219 shares of the stock traded hands, compared to its average volume of 156,058. USANA Health Sciences, Inc. has a 52-week low of $16.72 and a 52-week high of $38.32. The business has a fifty day simple moving average of $20.29 and a two-hundred day simple moving average of $21.88. The company has a market capitalization of $311.66 million, a price-to-earnings ratio of 30.70, a P/E/G ratio of 0.71 and a beta of 0.64.
USANA Health Sciences (NYSE:USNA – Get Free Report) last posted its earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The company had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. On average, research analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on USNA shares. Zacks Research raised shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.
Read Our Latest Research Report on USANA Health Sciences
Institutional Trading of USANA Health Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pzena Investment Management LLC raised its stake in shares of USANA Health Sciences by 1.2% in the third quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after acquiring an additional 14,328 shares during the period. Renaissance Technologies LLC boosted its stake in shares of USANA Health Sciences by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock worth $22,522,000 after purchasing an additional 21,793 shares during the period. Vanguard Group Inc. grew its holdings in USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after purchasing an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in USANA Health Sciences by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after purchasing an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences in the 4th quarter worth about $11,485,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.